Observational studyJournal of neurology2026
Two-year OCT follow-up in multiple sclerosis patients on Ofatumumab shows retinal preservation over non-antiCD20 treatments.
Observational study in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOptical coherence tomography (OCT) can detect neuroaxonal loss in multiple sclerosis (MS) patients, with thinning of the ganglion cell layer (GCL) reflecting neurodegeneration. Ofatumumab (OMB), a subcutaneous anti-CD20 monoclonal antibody, has demonstrated efficacy against inflammatory activity, though its neuroprotective potential is less established. This study aimed to assess longitudinal OCT changes in MS patients treated with OMB compared to those receiving non-anti-CD20 disease-modifying treatments (DMTs).
methodsThis longitudinal observational study included relapsing-remitting MS patients initiating Ofatumumab, with OCT and EDSS assessments at baseline and 24 months, compared with a retrospective control group on non-anti-CD20 DMTs. Eyes with prior optic neuritis were excluded. Longitudinal GCL thickness was analyzed using a nested linear mixed-effects model, including random intercepts for patients and eyes nested within patients and multivariate linear regression adjusting for baseline characteristics.
resultsWe analyzed 85 eyes from 47 patients (OMB: 46 eyes; control: 39 eyes). Baseline GCL was lower in OMB patients, who also had longer disease duration and higher EDSS. Over 24 months, GCL remained stable in OMB patients (+ 0.28 µm/year; p = 0.06), while controls showed significant thinning (- 0.99 µm/year; p < 0.001). In the adjusted multivariate regression model including age, sex, baseline GCL, EDSS, and disease duration, treatment with OMB was independently associated with reduced GCL loss (β = 2.41 µm/year, 95% CI 1.38-3.43, p < 0.001).
conclusionsOMB treatment was associated with significant retinal preservation, independent of baseline differences and confounders. These results suggest a potential neuroprotective effect of B-cell depletion in MS and support the utility of OCT as a sensitive biomarker for treatment monitoring.
Indexed as
Identifiers
41518393What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.